{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:43:55Z","timestamp":1792817035561,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.euo.2026.01.011","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:42:01Z","timestamp":1770727321000},"page":"673-689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-8226","authenticated-orcid":false,"given":"Martino","family":"Pedrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Salfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialuisa","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Tortola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasile","family":"Urechie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Barizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Paone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"Theurillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Merler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3123-3697","authenticated-orcid":false,"given":"Ricardo","family":"Pereira Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.01.011_b0005","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0010","unstructured":"International Agency for Research on Cancer. GLOBOCAN 2022, worldwide, both sexes, all ages. https:\/\/gco.iarc.fr\/today."},{"key":"10.1016\/j.euo.2026.01.011_b0015","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.01.011_b0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","article-title":"Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US Medicare population","volume":"27","author":"Freedland","year":"2024","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2026.01.011_b0025","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.01.011_b0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-020-00720-2","article-title":"Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the Prostate Cancer Registry","volume":"15","author":"Chowdhury","year":"2020","journal-title":"Target Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0035","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2024.07.013","article-title":"Systemic treatments for metastatic prostate cancer in 2024","volume":"10","author":"Gizzi","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.01.011_b0040","article-title":"Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review","author":"Francini","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.011_b0045","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.01.011_b0050","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.3390\/cancers12123792","article-title":"Neuroendocrine and aggressive-variant prostate cancer","volume":"12","author":"Spetsieris","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2026.01.011_b0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/iju.13526","article-title":"Clinical and molecular features of treatment-related neuroendocrine prostate cancer","volume":"25","author":"Akamatsu","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2026.01.011_b0060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","article-title":"Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes","volume":"12","author":"Aggarwal","year":"2014","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.euo.2026.01.011_b0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/PAP.0000000000000431","article-title":"Treatment-related neuroendocrine prostate carcinoma\u2014diagnostic and molecular correlates","volume":"31","author":"Gopalan","year":"2024","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.euo.2026.01.011_b0070","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.euo.2024.12.014","article-title":"Emergence of neuroendocrine tumors in patients treated with androgen receptor pathway inhibitors for metastatic prostate cancer: a systematic review and meta-analysis","volume":"8","author":"S\u00e9guier","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0075","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","article-title":"Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis\u2014a systematic review and pooled analysis","volume":"32","author":"Wang","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.euo.2026.01.011_b0085","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.01.011_b0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/ijms26010318","article-title":"The emerging predictive and prognostic role of aggressive-variant-associated tumor suppressor genes across prostate cancer stages","volume":"26","author":"Pedrani","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2026.01.011_b0095","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/bco2.212","article-title":"Genomic alterations in neuroendocrine prostate cancer: a systematic review and meta-analysis","volume":"4","author":"Chen","year":"2023","journal-title":"BJUI Compass"},{"key":"10.1016\/j.euo.2026.01.011_b0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.euo.2026.01.011_b0105","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2026.01.011_b0110","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.euo.2026.01.011_b0115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/XEB.0000000000000065","article-title":"Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness","volume":"13","author":"Tufanaru","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.euo.2026.01.011_b0120","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/JU.0000000000000001","article-title":"Guidelines for reporting of statistics for clinical research in urology","volume":"201","author":"Assel","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2026.01.011_b0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2307\/1267913","article-title":"Restricted maximum likelihood (REML) estimation of variance components in the mixed model","volume":"18","author":"Corbeil","year":"1976","journal-title":"Technometrics"},{"key":"10.1016\/j.euo.2026.01.011_b0130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.euo.2026.01.011_b0135","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1002\/sim.1262","article-title":"A simple confidence interval for meta-analysis","volume":"21","author":"Sidik","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2026.01.011_b0140","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.01.011_b0145","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41391-022-00524-7","article-title":"A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer","volume":"25","author":"Brown","year":"2022","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2026.01.011_b0150","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0155","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/j.clgc.2021.05.005","article-title":"Anaplastic features in advanced prostate cancer with and without DNA damage repair mutations","volume":"19","author":"Chau","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.01.011_b0160","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/pros.24400","article-title":"Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer","volume":"82","author":"Bray","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2026.01.011_b0165","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.clgc.2023.12.016","article-title":"Combined cabazitaxel and carboplatin treatment of metastatic castration resistant prostate cancer patients, with innate or acquired resistance to cabazitaxel monotherapy","volume":"22","author":"van der Zande","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.01.011_b0170","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/2767-9764.CRC-23-0175","article-title":"Concordance and clinical significance of genomic alterations in progressive tumor tissue and matched circulating tumor DNA in aggressive-variant prostate cancer","volume":"3","author":"Wang","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.euo.2026.01.011_b0175","doi-asserted-by":"crossref","first-page":"14948","DOI":"10.3390\/ijms232314948","article-title":"Salvage chemotherapy with cisplatin, ifosfamide, and paclitaxel in aggressive variant of metastatic castration-resistant prostate cancer","volume":"23","author":"von Amsberg","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2026.01.011_b0180","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.euros.2022.05.006","article-title":"Clinical efficacy of bipolar androgen therapy in men with metastatic castration-resistant prostate cancer and combined tumor-suppressor loss","volume":"41","author":"Markowski","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.01.011_b0185","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-022-02298-0","article-title":"Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer","volume":"20","author":"Mak","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.euo.2026.01.011_b0190","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1158\/1078-0432.CCR-19-4100","article-title":"Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer","volume":"26","author":"Malihi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.01.011_b0195","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1158\/1078-0432.CCR-23-3740","article-title":"A modular trial of androgen signaling inhibitor combinations testing a risk-adapted strategy in patients with metastatic castration\u2013resistant prostate cancer","volume":"30","author":"Aparicio","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.01.011_b0200","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.01.011_b0210","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/pros.24292","article-title":"DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy","volume":"82","author":"Zhu","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2026.01.011_b0215","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/jjco\/hyad011","article-title":"Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancer","volume":"53","author":"Ueki","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0220","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-23-0536","article-title":"Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: a phase I clinical trial","volume":"29","author":"Abel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.01.011_b0225","article-title":"Treatment-emergent neuroendocrine prostate cancer: a clinicopathological and immunohistochemical analysis of 94 cases","volume":"10","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0230","doi-asserted-by":"crossref","first-page":"74.e17","DOI":"10.1016\/j.urolonc.2020.07.007","article-title":"Specificities of small cell neuroendocrine prostate cancer: adverse prognostic value of TTF1 expression","volume":"39","author":"Cancel","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0235","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41391-017-0017-6","article-title":"Platinum sensitivity in metastatic prostate cancer: does histology matter?","volume":"21","author":"Humeniuk","year":"2018","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2026.01.011_b0240","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.clgc.2023.04.008","article-title":"Outcomes of second-line therapies in patients with metastatic de novo and treatment-emergent neuroendocrine prostate cancer: a multi-institutional study","volume":"21","author":"Eule","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.01.011_b0245","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.21873\/anticanres.15699","article-title":"Treatment outcomes in neuroendocrine prostate cancer","volume":"42","author":"Iwamoto","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euo.2026.01.011_b0250","doi-asserted-by":"crossref","first-page":"729.e7","DOI":"10.1016\/j.urolonc.2020.12.002","article-title":"Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy","volume":"39","author":"van der Doelen","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0255","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","article-title":"Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with lutetium-177-PSMA-617","volume":"57","author":"Crumbaker","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.01.011_b0260","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.778758","article-title":"Neuroendocrine carcinoma as an independent prognostic factor for patients with prostate cancer: a population-based study","volume":"12","author":"Yao","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.euo.2026.01.011_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102172","article-title":"The use of lurbinectedin for the treatment of small cell and neuroendocrine carcinoma of the prostate","volume":"22","author":"Meyer","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.01.011_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102274","article-title":"Real-world clinical outcomes and prognostic factors in neuroendocrine prostate cancer","volume":"23","author":"Gagnon","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.01.011_b0275","article-title":"PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell\/neuroendocrine bladder and prostate cancers","volume":"5","author":"Gu","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.euo.2026.01.011_b0280","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3390\/life15050797","article-title":"Local therapy can enhance the prognosis of certain patients with pathologically diagnosed neuroendocrine prostate carcinoma","volume":"15","author":"Kimura","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.euo.2026.01.011_b0285","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"2 Suppl","key":"10.1016\/j.euo.2026.01.011_b0290","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/jco.2016.34.2_suppl.268","article-title":"Prognostic impact of clinical and pathologic criteria in neuroendocrine and aggressive variant prostate cancer","volume":"34","author":"Karir","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2026.01.011_b0295","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2023.41.6_suppl.196","article-title":"Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel-carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC)","volume":"41","author":"Pili\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2026.01.011_b0300","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1200\/JCO.2017.35.6_suppl.e575","article-title":"Predictors of response to platinum (Pt)-based chemotherapy in metastatic castration-resistant prostate cancer (mCRPC)","volume":"35","author":"Kilari","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.euo.2026.01.011_b0305","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/jco.2012.30.5_suppl.190","article-title":"Neuroendocrine prostate cancer (NEPC) after androgen deprivation therapy (ADT): clinical characteristics","volume":"30","author":"Akhtar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.euo.2026.01.011_b0310","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1200\/JCO.2022.40.16_suppl.5055","article-title":"Biallelic loss of TP53, PTEN, and RB1 in association to aggressive clinical features and poor outcomes in metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Maurice-Dror","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2026.01.011_b0315","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1200\/jco.2015.33.15_suppl.5003","volume":"33","author":"Small","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2026.01.011_b0320","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1200\/JCO.2023.41.6_suppl.176","article-title":"First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: phase 2a final results","volume":"41","author":"Aggarwal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0325","first-page":"74","article-title":"UOP-1259\u2003Clinical outcome of EP therapy (VP16 + CDDP) in 10 prostate cancer patients with neuroendocrine differentiation","volume":"27","author":"Terakawa","year":"2020","journal-title":"Int J Urol"},{"issue":"5 Suppl","key":"10.1016\/j.euo.2026.01.011_b0330","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2025.43.5_suppl.259","article-title":"Evaluating survival in aggressive variant prostate cancer patients undergoing PSMA radioligand therapy","volume":"43","author":"Moradpour","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.euo.2026.01.011_b0335","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/JCO.2025.43.5_suppl.171","article-title":"Targeting TROP2 in aggressive variant and neuroendocrine prostate cancer","volume":"43","author":"Von Amsberg","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0340","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/pcan.2013.41","article-title":"Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"17","author":"Goodman","year":"2014","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2026.01.011_b0345","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.clgc.2017.02.007","article-title":"Effect of visceral disease site on outcomes in patients with metastatic castration-resistant prostate cancer treated with enzalutamide in the PREVAIL trial","volume":"15","author":"Alumkal","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.01.011_b0350","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.euros.2024.06.006","article-title":"Survival patterns based on first-site\u2013specific visceral metastatic prostate cancer: are outcomes of visceral metastases the same?","volume":"66","author":"Ahmed","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.01.011_b0355","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/j.clgc.2022.05.009","article-title":"Complete response in patients with lung-only metastatic prostate cancer: outcome analysis","volume":"20","author":"Kase","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2026.01.011_b0360","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2019.37.15_suppl.5052","article-title":"Aggressive variant prostate cancer (AVPC) molecular signature in castration-sensitive, de novo metastatic prostate cancer (M1PCa)","volume":"37","author":"Aparicio","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0365","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy284.023","article-title":"Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects: a multicentre retrospective analysis","volume":"29","author":"Gillessen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.01.011_b0370","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis","volume":"87","author":"Naqvi","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.01.011_b0375","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.euo.2026.01.011_b0380","first-page":"339","article-title":"Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs","volume":"14","author":"Turco","year":"2022","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.euo.2026.01.011_b0385","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/iju.15378","article-title":"Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer","volume":"31","author":"De Velasco","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2026.01.011_b0390","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf6724","article-title":"Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies","volume":"15","author":"Shi","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.euo.2026.01.011_b0395","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.01.011_b0400","unstructured":"AstraZeneca. Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 phase III trial. Press release November 25, 2024. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/truqap-improved-rpfs-in-advanced-prostate-cancer.html."}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126000325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:42:23Z","timestamp":1783197743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126000325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2588931126000325"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.01.011","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}